DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

PR Newswire

MELBOURNE, Australia, June 16, 2026

Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia500,000-1 million people are estimated to be living with FSGS in the territories[1]Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royaltiesUS$10 million (~AU$14.1 million2) upfront paymentUp to US$330 million (~AU$467 million2) in potential milestone paymentsTiered royalties on net salesEverest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma (announced October 2023)[3], Taiba Rare (announced May 2024)[4], Fuso Pharmaceutical Industries (announced 7 January 2025)[5], and Amicus Therapeutics (announced 1 May 2025, now BioMarin)[6]; with over AU$65 million having been received prior to the Everest transactionCollectively across the 5 transactions, Dimerix may be eligible to receive up to ~AU$1.9 billion[7] in aggregate total upfront and potential milestone payments, plus additional royalties on net salesDMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and serious kidney disease with no approved therapies across these regionsThe ACTION3 Phase 3 clinical trial is fully recruited, with patients enrolled across 21 countries, including Chinese mainland, Hong Kong SAR, Taiwan region, Thailand and MalaysiaEverest will leverage its specialty kidney disease expertise and commercial platform to register and commercialise DMX-200, offering greater patient access to the growing Asian marketsDimerix retains all rights to DMX-200 in all other unlicensed territoriesMELBOURNE, Australia, June 16, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") today announced that it has entered into an exclusive license agreement with Everest Medicines for the commercialisation of Dimerix's Phase 3 drug candidate DMX-200 for all indications including FSGS, in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). Dimerix retains all rights to commercialise DMX-200 in all territories other than those already exclusively licensed.